Drug Profile

Relaxin-2 - Relaxera

Latest Information Update: 08 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Relaxera Pharmazeutische Gesellschaft
Class Heart failure therapies; Peptide hormones
Mechanism of Action Relaxin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Heart failure

Most Recent Events

08 Feb 2026 Relaxera Pharmaceuticals plans phase I/II Relax-in-AF trial in Atrial fibrillation in January 2027 (SC) (NCT07359872)
31 Jan 2026 Relaxera has patent protection for Relaxin-2 for Heart failure, prior January 2026 (Relaxera pipeline, January 2026)
22 Jan 2026 Relaxin is still in preclinical development in Heart-failure in Germany (Parenteral) (Relaxera pipeline, January 2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com